Metabolomic profiling of bile acids in clinical and experimental samples of Alzheimer’s disease

Metabolites

Volumn 7, Issue 2, 2017, Pages

  Pan, Xiaobei ^a   Elliott, Christopher T ^a   McGuinness, Bernadette ^b   Passmore, Peter ^b   Kehoe, Patrick G ^c   Hölscher, Christian ^d   McClean, Paula L ^e   Graham, Stewart F ^f   Green, Brian D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF ULSTER   (United Kingdom)

^f Beaumont Research Institute   (United States)

Author keywords

Alzheimer s disease; Bile acids; Metabolites; Metabolomics

Indexed keywords

ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLITHOCHOLIC ACID SULPHATE; GLYCOURSODEOXYCHOLIC ACID; HYODEOXYCHOLIC ACID; LITHOCHOLIC ACID; OMEGA MURICHOLIC ACID; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; TAUROLITHOCHOLIC ACID SULPHATE; TAUROMURICHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; METABOLISM; MOUSE; MULTIPLE REACTION MONITORING; NONHUMAN; POLYMERASE CHAIN REACTION; QUADRUPOLE MASS SPECTROMETRY; RECEIVER OPERATING CHARACTERISTIC; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 85021330532     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo7020028     Document Type: Article

References (35)

1. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7, 678-693.
2. Perino, A., Schoonjans, K. TGR5 and immunometabolism: Insights from physiology and pharmacology. Trends Pharmacol. Sci. 2015, 36, 847-857.
3. Fan, J., Donkin, J., Wellington, C. Greasing the wheels of Abeta clearance in Alzheimer’s disease: The role of lipids and apolipoprotein E. Biofactors 2009, 35, 239-248.
4. Ogundare, M., Theofilopoulos, S., Lockhart, A., Hall, L.J., Arenas, E., Sjovall, J., Brenton, A.G., Wang, Y., Griffiths, W.J. Cerebrospinal fluid steroidomics: Are bioactive bile acids present in brain? J. Biol. Chem. 2010, 285, 4666-4679.
5. Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S., Legido-Quigley, C. A proposed metabolic strategy for monitoring disease progression in Alzheimer’s disease. Electrophoresis 2009, 30, 1235-1239.
6. Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., et al. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer’s disease. J. Alzheimers Dis. 2015, 45, 1157-1173.
7. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., Hall, W.J., Fisher, S.G., Peterson, D.R., Haley, J.M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20, 415-418.
8. Mano, N., Goto, T., Uchida, M., Nishimura, K., Ando, M., Kobayashi, N., Goto, J. Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. J. Lipid Res. 2004, 45, 295-300.
9. Mano, N., Sato, Y., Nagata, M., Goto, T., Goto, J. Bioconversion of 3β-hydroxy-5-cholenoic acid into chenodeoxycholic acid by rat brain enzyme systems. J. Lipid Res. 2004, 45, 1741-1748.
10. Ferdinandusse, S., Denis, S., Faust, P.L., Wanders, R.J. Bile acids: The role of peroxisomes. J. Lipid Res. 2009, 50, 2139-2147.
11. Ramalho, R.M., Borralho, P.M., Castro, R.E., Solá, S., Steer, C.J., Rodrigues, C.M. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cells. J. Neurochem. 2006, 98, 1610-1618.
12. Keene, C.D., Rodrigues, C.M., Eich, T., Chhabra, M.S., Steer, C.J., Low, W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc. Natl. Acad. Sci. USA 2002, 99, 10671-10676.
13. Duan, W.M., Rodrigues, C.M., Zhao, L.R., Steer, C.J., Low, W.C. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson’s disease. Cell Transplant. 2002, 11, 195-205.
14. Yanguas-Casás, N., Barreda-Manso, M.A., Nieto-Sampedro, M., Romero-Ramírez, L. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. J. Neuroinflamm. 2014, 11, 50.
15. Graham, S.F., Chevallier, O.P., Roberts, D., Hölscher, C., Elliott, C.T., Green, B.D. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer’s disease. Anal. Chem. 2013, 85, 1803-1811.
16. Graham, S.F., Holscher, C., McClean, P.L., Elliott, C.T., Green, B. 1H NMR metabolomics investigation of an Alzheimer’s disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. Metabolomics 2013, 9, 974-983.
17. Graham, S.F., Holscher, C., Green, B.D. Metabolic signatures of human Alzheimer’s disease (AD): 1H-NMR analysis of the polar metabolome of post-mortem brain tissue. Metabolomics 2014, 10, 744-753.
18. Graham, S.F., Chevallier, O.P., Elliott, C.T., Hölscher, C., Johnston, J., McGuinness, B., Kehoe, P.G., Passmore, A.P., Green, B.D. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer’s disease. PLoS ONE 2015, 10, e0119452.
19. Proitsi, P., Kim, M., Whiley, L., Pritchard, M., Leung, R., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease. Transl. Psychiatry 2015, 5, e494.
20. Fraser, T., Tayler, H., Love, S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem. Res. 2010, 35, 503-513.
21. Nasaruddin, M.L., Hölscher, C., Kehoe, P., Graham, S.F., Green, B.D. Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer’s disease as detected by GC-MS. Am. J. Transl. Res. 2016, 8, 154-165.
22. Pan, X., Nasaruddin, M.B., Elliott, C.T., McGuinness, B., Passmore, A.P., Kehoe, P.G., Hölscher, C., McClean, P.L., Graham, S.F., Green, B.D. Alzheimer’s disease-like pathology has transient effects on the brain and blood metabolome. Neurobiol. Aging 2016, 38, 151-163.
23. Weill-Engerer, S., David, J.P., Sazdovitch, V., Liere, P., Eychenne, B., Pianos, A., Schumacher, M., Delacourte, A., Baulieu, E.E., Akwa, Y. Neurosteroid quantification in human brain regions: Comparison between Alzheimer’s and nondemented patients. J. Clin. Endocrinol. Metab. 2002, 87, 5138-5143.
24. Volianskis, A., Kostner, R., Molgaard, M., Hass, S., Jensen, M.S. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1 Delta E9-deleted transgenic mice model of beta-amyloidosis. Neurobiol. Aging 2010, 31, 1173-1187.
25. Xiong, H., Callaghan, D., Wodzinska, J., Xu, J., Premyslova, M., Liu, Q.-Y., Connelly, J., Zhang, W. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer’s disease. Neurosci. Bull. 2011, 27, 221-232.
26. Glossmann H. The Bile Acid Metabolome in Humans and Rodents, Biocrates Commentary. Available online: http://www.biocrates.com/images/Glossmann2015_HumansANDRodents.pdf (accessed on 12 January 2016).
27. Jones, M.L., Martoni, C.J., Ganopolsky, J.G., Labbé, A., Prakash, S. The human microbiome and bile acid metabolism: Dysbiosis, dysmetabolism, disease and intervention. Expert Opin. Biol. Ther. 2014, 14, 467-482.
28. Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E., Hatton, G.E., Nelson, A.M., Li, B., Huffnagle, G.B., Li, J.Z., Young, V.B. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 2014, 5, 3114.
29. Hackshaw, A. Small studies: Strengths and limitations. Eur. Respir. J. 2008, 32, 1141-1114.
30. Axelson, M., Mörk, B., Sjövall, J. Occurrence of 3β-hydroxy-5-cholestenoic acid, 3β,7α-dihydroxy-5-cholestenoic acid, and 7α-hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood. J. Lipid Res. 1988, 29, 629-641.
31. Nagata, K., Takakura, K., Asano, T., Seyama, Y., Hirota, H., Shigematsu, N., Shima, I., Kasama, T., Shimizu, T. Identification of 7α-hydroxy-3-oxo-4-cholestenoic acid in chronic subdural hematoma. Biochim Biophys. Acta 1992, 1126, 229-236.
32. Nagata, K., Seyama, Y., Shimizu, T. Changes in the level of 7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid after subarachnoid hemorrhage. Neurol. Med. Chir. 1995, 35, 294-297.
33. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M. Clinical diagnosis of alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of healthand human services task force on Alzheimer’s disease. Neurology 1984, 34, 939-944.
34. Urban, M., Enot, D.P., Dallmann, G., Korner, L., Forcher, V., Enoh, P., Koal, T., Keller, M., Deigner, H.P. Complexity and pitfalls of mass spectrometry-based targeted metabolomics in brain research. Anal. Biochem. 2010, 406, 124-131.
35. Xia, J., Sinelnikov, I.V., Han, B., Wishart, D.S. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 2015, 43, W251-W257.